In ovarian cancer, RNA-modification regulatory genes (RRGs) are critical drivers of tumorigenesis and drug resistance, with ALKBH5 promoting cancer progression through the NF-κB pathway and IGF2BP3 contributing to platinum resistance, highlighting their role in shaping cancer biology and therapeutic responses [123]. This evidence concerns the gene ALKBH5 and ovarian carcinoma.